Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Review
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 11,942 | Dovepress* | 10,517+ | 1,741 | 12,258 | |
| PubMed Central* | 1,425 | 497 | 1,922 | ||
| Totals | 11,942 | 2,238 | 14,180 | ||
| *Since 16 October 2017 | |||||
| Total mentioned | Delicious | Others | |||
|---|---|---|---|---|---|
| 30 | 1 | 0 | 0 | 14 | 15 |
View citations on PubMed Central and Google Scholar